Clinical Trial Update: Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma [Phase 1]

View source ↗

Summary

Phase 1 biomarker study of an anti-PD-L1 agent for advanced melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• PD-L1 inhibitor (anti-PD-L1) (PD-L1 inhibitor)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Stage III or IV Melanoma | Phase 1 | Status: WITHDRAWN